Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astrana HealthASTH -0.08%87 3-Year FCF Growth Rate is 17.70% as of Jun. 2026, which is 142% above its 10-year median of 7.30. GuruFocus rates ASTH with a GF Score™ of 87/100 and a GF Value™ of $66.06 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 463 Healthcare Providers & Services companies, Astrana Health ranks better than 53.78% on this metric.
During the past 12 months, Astrana Health's average Free Cash Flow per Share Growth Rate was -22.20% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 17.70% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 5.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Astrana Health was 55.20% per year. The lowest was -63.50% per year. And the median was 7.30% per year.
Astrana Health (NAS:ASTH) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Astrana Health 3-Year FCF Growth Rate Related Terms
ASTH vs SNDA, SGRY, ADUS: 3-Year FCF Growth Rate Comparison
For the Medical Care Facilities subindustry, Astrana Health's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astrana Health 3-Year FCF Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Astrana Health's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Astrana Health's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 17.70% mean?
Astrana Health (ASTH) has a 3-Year FCF Growth Rate of 17.70% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Astrana Health and its competitors. This is 142% above median its historical median of 7.30. According to the industry distribution chart, Astrana Health ranks #214 out of 463 companies in the Healthcare Providers & Services industry, placing it in the top 46.2%.
Is Astrana Health's 3-Year FCF Growth Rate too high?
Astrana Health's current 3-Year FCF Growth Rate of 17.70% is 142% above median its 10-year median of 7.30. The Healthcare Providers & Services industry median 3-Year FCF Growth Rate is 12.30. Astrana Health's value of 17.70% is 43.9% above this industry median. Based on the distribution chart, Astrana Health ranks #214 out of 463 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Astrana Health has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astrana Health's 3-Year FCF Growth Rate compare to SNDA and SGRY?
According to the Healthcare Providers & Services industry distribution chart, Astrana Health ranks #214 out of 463 companies for 3-Year FCF Growth Rate. This puts Astrana Health in the upper half of its industry. The industry median 3-Year FCF Growth Rate is 12.30. Astrana Health's value of 17.70% is 43.9% above this benchmark. While the company's 10-year median is 7.30 vs. the industry median of 12.30, Astrana Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Healthcare Providers & Services company?
The median 3-Year FCF Growth Rate among Healthcare Providers & Services companies is 12.30, based on 463 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astrana Health's current 3-Year FCF Growth Rate of 17.70% is 43.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Astrana Health and its competitors. For the Healthcare Providers & Services industry, the median 3-Year FCF Growth Rate is 12.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astrana Health's current 3-Year FCF Growth Rate is 17.70%, which is 142% above median its own 10-year median of 7.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astrana Health stock overvalued right now?
Based on GuruFocus' analysis, Astrana Health (ASTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $66.06, compared to a current price of $38.57 — trading 41.6% below its estimated fair value. The current 3-Year FCF Growth Rate is 17.70%, which is 142% above median its 10-year median of 7.30 and 43.9% above the Healthcare Providers & Services industry median of 12.30. Astrana Health's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Astrana Health (ASTH), the current 3-Year FCF Growth Rate is 17.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astrana Health (ASTH) Overvalued in 2026?
Based on GuruFocus' analysis, Astrana Health stock appears to be undervalued.
The current stock price of $38.57 is trading 41.6% below its estimated GF Value™ of $66.06.
GuruFocus considers Astrana Health to be Significantly Undervalued.
Key valuation signals for ASTH:
3-Year FCF Growth Rate: 17.70% (142% above median its 10-year median of 7.30)
GF Value™: $66.06 vs. price of $38.57 (41.6% below fair value)
Industry Position: 43.9% above the Healthcare Providers & Services median (#214 of 463)
No single metric tells the full story. See the ASTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
87GF Score
Get the complete analysis for ASTH
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASTH has been successfully added to your 
